AveXis logo

AveXis

Specializing in groundbreaking gene therapies for rare neurological genetic diseases, impacting lives profoundly.

est. 2013

VS
Noema Pharma logo

Noema Pharma

A clinical-stage biotech pioneering a portfolio of disease-transforming therapeutics for CNS-mediated conditions

33 employees · est. 2019 · Basel, Switzerland

AveXis is the older company (2013 vs 2019).

Side-by-Side Comparison

AveXis Noema Pharma
Founded
2013 older 2019
Headquarters
Not tracked yet Basel, Switzerland
Employees
Not tracked yet 33
Industry
Biotechnology, Health Care Biotechnology, Pharmaceutical
Funding Stage
Grant Series B
Total Funding
$75.10M $184.00M
Funding Rounds
5 3
Services
Not tracked yet Development of oral small molecule therapeutics, Advancement of clinical-stage programs, Strategic collaborations with investors and partners, Educational resource provision for patients
Target Customers
Not tracked yet Patients with neurological disorders, Individuals experiencing menopause-related symptoms, Healthcare providers, Investors interested in biotech and pharmaceutical innovations
Taxonomy
Gene Therapy, Neurological Genetic Diseases, Rare Diseases, Medical Innovation, Novartis, Acquisition, Life-Threatening Conditions, Research & Development, Therapeutic Innovations Biotech, Clinical-stage, Therapeutics Development, CNS-mediated Conditions, Orphan Brain Disorders, Neurological Diseases, Patient-centered Research, Novel Therapies, Symptom Management, R&D
Website
avexis.com noemapharma.com
AveXis logo

About AveXis

AveXis is a biotechnology startup specializing in groundbreaking gene therapies for rare neurological genetic diseases, impacting lives profoundly. Founded in 2013, the company was later acquired by Novartis on May 14, 2018, and adopted the name Novartis Gene Therapies in 2020. AveXis focuses on dev...

Noema Pharma logo

About Noema Pharma

Noema Pharma, founded in 2019, is a promising clinical-stage biotech company headquartered in Switzerland. The company’s mission is captured in its slogan: "A clinical-stage biotech pioneering a portfolio of disease-transforming therapeutics for CNS-mediated conditions." They are on the frontier of...

Be first to know when either one moves

Funding rounds, hiring surges, leadership changes and stack switches at AveXis and Noema Pharma — tracked continuously, sent the day they land.

Watch both — free

Funding, hiring, leadership and stack changes at AveXis and Noema Pharma — by email.

Frequently Asked Questions

AveXis — Specializing in groundbreaking gene therapies for rare neurological genetic diseases, impacting lives profoundly.. Noema Pharma — A clinical-stage biotech pioneering a portfolio of disease-transforming therapeutics for CNS-mediated conditions. Both companies operate in related markets but may differ in funding stage, team size, and product focus.
AveXis has raised $75.10M while Noema Pharma has raised $184.00M.
AveXis and Noema Pharma operate in overlapping markets and are frequently compared. Track both companies on Bounce Watch to monitor their growth signals in real time.

Compare AveXis with someone else

Start typing a company name or domain.

One analytics cookie (Google Analytics). Cookie Policy